Ovoca Bio Plc (OVB) Euro 0.125
- Add to watchlist
- Create an alert
- This stock can be held in a
Business summary
Ovoca Bio PLC is a clinical-stage biopharmaceutical company focused on women’s health. The Company is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. It is also developing a new treatment for women affected by low libido or sex drive. It owns a patent portfolio that provides effective protection of its technology. The Company operates in Ireland, the United Kingdom and Russia.
Contact details
Important dates
General stock information
- EPIC:
- OVB
- ISIN:
- IE00B4XVDC01
- Market cap:
- £672,901
- Shares in issue:
- 81.56 million
- Sector:
- Mining
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.